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Serum β2-microglobulin levels at diagnosis and during antitumour treatment
in children with malignant neoplasms
Ewa Bieƒ1, Anna Balcerska1, Dominik Ciesielski2
O b j e c t i v e.  To assess whether serum β2-Microglobulin (β2-M) levels might serve as a marker for both diagnostics and
treatment monitoring in children with cancer.
M a t e r i a l s  a n d  m e t h o d s.  Serum β2-M levels and rates of β2-M elevated values were estimated by ELISA in 100
children with acute leukaemia and lymphomas (n=64) and with malignant solid tumours (n=36). The study was performed
prospectively, the analyses were performed before treatment, in partial and complete remission, after therapy and during relapse
or progression of cancer. The control group consisted of 30 healthy children.
R e s u l t s.  Median pre-treatment β2-M levels in children with lymphoproliferative disorders were significantly elevated as
compared to controls. This was not observed in the case of malignant solid tumours. β2-M elevated rates were 66.7% in patients
with leukaemias and lymphomas and only 33.7% in solid tumours. The good response to antitumour therapy in the entire
oncological group parallelled a significant decrease of pre-treatment β2-M levels towards normal range (p<0.001).
C o n c l u s i o n s.  β2-M may serve as a useful diagnostic marker in paediatric lymphoproliferative disorders, but not in the case
of malignant solid tumours. Monitoring of serum concentrations of β2-M during oncological treatment may be of value,
especially in children with lymphoproliferative neoplasms, however further studies are necessary in more homogenous and
numerous group of patients.
Poziomy β2-mikroglobuliny w surowicy krwi w momencie rozpoznania 
i w trakcie terapii choroby nowotworowej u dzieci
C e l.  Celem pracy by∏a ocena klinicznej przydatnoÊci oznaczania surowiczego poziomu β2-Mikroglobuliny ( β2-M) w diagno-
styce i monitorowaniu efektów leczenia u dzieci z chorobà nowotworowà.
M a t e r i a ∏  i m e t o d y.  Poziomy β2-M w surowicy oznaczano przy u˝yciu metody ELISA w grupie 100 dzieci z rozpoznaniem
ostrych bia∏aczek i ch∏oniaków z∏oÊliwych (n=64) oraz z∏oÊliwych guzów litych (n=36). Grup´ kontrolnà stanowi∏o 30 zdro-
wych dzieci. Poziom β2-M oraz odsetki podwy˝szonych wartoÊci β2-M u pacjentów onkologicznych oznaczano prospektywnie
na pi´ciu etapach choroby: przed leczeniem, w fazie cz´Êciowej i ca∏kowitej klinicznej remisji choroby, po zakoƒczeniu tera-
pii oraz w okresie wznowy, bàdê progresji nowotworu.
W y n i k i.  Âredni poziom β2-M, oznaczony w momencie rozpoznania choroby u dzieci ze schorzeniami limfoprolifera-
cyjnymi, znaczàco przewy˝sza∏ wartoÊci stwierdzone u zdrowych dzieci, podczas gdy u pacjentów z rozpoznaniem nowotwo-
rów litych nie odbiega∏ od normy. Podwy˝szone wartoÊci β2-M stwierdzono u wi´kszoÊci (66,7%) pacjentów z rozrostowymi
schorzeniami uk∏adu krwiotwórczego i jedynie u 33,7% chorych z guzami litymi. W trakcie leczenia przeciwnowotworowego,
wraz z osiàganà pozytywnà odpowiedzià klinicznà, poziom β2-M obni˝a∏ si´ do wartoÊci prawid∏owych (p<0,001).
W n i o s k i.  Oznaczanie β2-M mo˝e s∏u˝yç jako wartoÊciowy marker diagnostyczny u dzieci ze schorzeniami rozrostowymi uk∏a-
du krwiotwórczego, nie ma natomiast znaczenia w rozpoznawaniu z∏oÊliwych guzów litych wieku dzieci´cego. Monitorowa-
nie poziomów β2-M w trakcie leczenia onkologicznego ma pewne znaczenie kliniczne, zw∏aszcza u dzieci z chorobami limfo-
proliferacyjnymi, jednak spostrze˝enie to wymaga potwierdzenia w bardziej jednorodnej i liczebnej grupie chorych.
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Introduction
β2-Microglobulin ( β2-M) is a low molecular weight non-
glycosylated protein (11800 D) which constitutes the light
chain of the class I major histocompatibility complex
(MHC) [1]. It is present on the surface of most nucleated
cells (mainly lymphocytes T, B and macrophages) [2] while
membrane turnover is its principal source in blood and
body fluids [3]. Immune activation results in an increased
release of β2-M into circulation and high levels of this
protein have been found in a variety of infectious,
inflammatory and autoimmune conditions [4-6]. The exact
role of β2-M in carcinogenesis and the reasons for its
increased levels in the course of malignancy remain
unknown. It has been shown that some tumours demon-
strate decreased expression of β2-M. This may serve as
one of the mechanisms of escaping immune surveillance
and progressing to metastases [7, 8]. However, signi-
ficantly elevated serum β2-M levels have been observed in
numerous neoplasms, especially of the lymphoprolifera-
tive type, correlating with tumour mass, stage and
prognosis. [9-12]. Clinical usefulness of β2-M determi-
nation in most malignant solid tumours of adults was
shown to be rather limited [13-15].
To the best of our knowledge, there have been no
reports regarding the clinical significance of serum β2-M
in children with cancer. In view of the considerable
histological, biological and clinical differences between
childhood and adult malignancies, it seemed reasonable
to investigate the issue. Thus, in the present study we
have attempted to determine the significance of β2-M
measurements both in the diagnostics and in treatment
monitoring of lymphoproliferative and malignant solid
tumours in children.
Material and method
We enrolled 100 children with neoplastic disease, treated in the
Division of Haematology and Oncology of the Department of
Paediatrics, Haematology, Oncology and Endocrinology of the
Medical University of Gdansk in Poland between the years 1995
and 2000. The group covered six histological types of childhood
malignancies, i.e.: acute lymphoblastic leukaemia (ALL), acute
non-lymphoblastic leukaemia (ANLL), non-Hodgkin lymphoma
(NHL), Hodgkin’s disease (HD), Wilms’ tumour (Tu Wilms)
and soft tissue sarcomas (SA). The diagnosis, staging, treatment
and assessment of response to therapy were carried out in
accordance to schemes provided by the International Society
of Paediatric Oncology (SIOP) and Polish Paediatric Leu-
kaemia/Lymphoma and Solid Tumours Study Groups for each
particular type of malignancy. Pathological examinations were
verified in two different institutions. Control group consisted
of 30 healthy children. The clinical characteristics of patients
and controls are shown in Table I.
In the case of patients with cancer the serum levels of β2-M
were determined in a prospective manner at five time points:
before treatment (at diagnosis), in partial (PR) and complete
clinical remission (CR), after therapy and during relapse or
progression of cancer (PROG). The pre-treatment deter-
mination of β2-M was carried out in both the entire oncological
group and each type of neoplasm. Rates of elevated β2-M
measurements (>2.6 mg/L) were estimated for each type of
malignancy and each phase of disease course. In the control
group serum β2-M levels were evaluated once after obtaining
informed consent confirmed by parental signature.
The study had been approved by the Local Ethics
Committee (decision nr 367/95).
β 2 - M i c r o g l o b u l i n  A s s a y
Blood collected from patients and controls was centrifuged at
2000 rpm for 15 minutes to separate serum. Serum samples
were stored frozen at –70°C until assayed. Measurements of 
β2-M levels were performed in duplicate with the enzyme-linked
immunosorbent assay (ELISA) (β2-Microglobulin enzyme
immunoassay, ref. nr 1131, Immunotech, France). The results
were expressed in mg/L. To exclude a possible influence of renal
impairment on serum β2-M determinations, serum blood urea
nitrogen (BUN) and creatinine level were checked. They were
normal in all patients and controls at the time of sample
collection
S t a t i s t i c a l  A n a l y s i s
Statistical analysis was performed using Statistica 5.0 and 
S-PLUS software. Data distribution was checked with the
Ko∏mogorow-Smirnow test, and all results of β2-M deter-
minations underwent statistical analysis with the use of non-
parametric tests (Mann-Whitney U-test, Wilcoxon’s test).
Statistical significance level was set for p<0,05.
Results
β 2 - M  l e v e l s  a n d  r a t e s  o f  i t s  e l e v a t e d
v a l u e s  a t  d i a g n o s i s  o f  m a l i g n a n t  d i s e a s e
Results of serum concentration of β2-M at diagnosis
of malignancy and in controls are reported in Table II.
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Table I. Clinical characteristics of cancer patients and of the control group
Patients Number Sex Mean age in years
(% of all) F / M (age range)
Oncological group 100 (100%) 45 / 55 6.9 (0.3-16.9)
Lympho-proliferative disorders ALL 38 (38%) 15 / 23 6.0 (2.0-14.8)
ANLL 3 (3%) 2 / 1 5.8 (3.4-10.0)
NHL 11 (11%) 1 / 10 9.1 (3.9-14.7)
HD 12 (12%) 5 / 7 12.4 (5.0-16.9)
Malignant solid tumours Tu Wilms 19 (19%) 11 / 8 4.1 (0.9-10.6)
SA 17 (17%) 11 / 6 7.0 (0.3-13.1)
Control group 30 (100%) 15 / 15 8.8 (2.3-16.6)
The values did not depend on sex or age. The median
pre-treatment level of β2-M determined for the entire
malignancy group was significantly higher, as compared to
healthy children (p<0.001). However, significant diffe-
rences in pre-treatment β2-M levels were observed, when
analysed in particular histological types of neoplasms.
We have found that the serum concentrations of β2-M at
the diagnosis of acute leukaemias and Hodgkin and non-
Hodgkin lymphomas were significantly higher than in the
control group (p<0.001 for ALL, p<0.05 for ANLL,
NHL and HD). On the contrary, in children with Tu
Wilms and SA the β2-M levels did not differ from healthy
controls (p>0.05). The rates of elevated initial β2-M
values for the entire group of cancer patients,
lymphoproliferative disorders and solid neoplasms were
of 55.7%, 66.7% and 33.7%, respectively.
β 2 - M  l e v e l s  a n d  r a t e s  o f  i t s  e l e v a t e d
v a l u e s  a t  d i f f e r e n t  s t a g e s  o f  n e o p l a s t i c
d i s e a s e
β2-M serum concentrations in children with neoplasms
at different stages of disease are shown in Table II.
Median β2-M concentration determined at diagnosis for
the entire oncological group significantly exceeded the
levels observed at complete clinical remission (CR) –
both during treatment and after the termination of
therapy (p<0.001 and p<0.05 respectively). It was shown
that on obtaining CR of cancer, β2-M concentrations
decreased towards normal range. In the case of 14
patients with relapse or progression (PROG), the serum
β2-M levels returned to values similar to those found at
diagnosis, however the difference between CR and
PROG was not statistically significant (p>0.05).
Since we have shown significant differences in the
pre-treatment β2-M levels in children with lympho-
proliferative disorders and malignant solid tumours, the
changes in β2-M levels during treatment in patients with
ALL+ ANLL+NHL+HD and with Tu Wilms+SA were
analysed separately (Figures 1 and 2). The changes in 
β2-M concentrations seem to reflect the activity and
course of lymphoproliferative diseases, while their
monitoring role in Tu Wilms and SA patients is uncertain.
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Table II. The results of serum β2-M at diagnosis and at different time points of oncological treatment as compared to healthy controls
Stage of disease β2-M (mg/l)
(number of patients) mean ± SD median (values range) % of > 2.6 mg/l
pre-treatment (n=61) 3.15 ± 1.70 2.80 (1.2 – 10.6) ** #Ψ 55.7
ALL 3.67 ± 2.20 3.20 (1.2 – 10.6)** 68.2
ANLL 2.80 ± 0.50 3.20 (1.2 – 10.6)* 66.7
NHL 3.05 ± 0.90 2.80 (2.3 – 3.3)* 66.7
HD 3.04 ± 0.98 3.20 (1.6 – 4.0)* 66.7
Tu Wilms 2.78 ± 1.93 2.15 (1.2 – 7.8) 30.0
SA 2.53 ± 1.23 2.25 (1.2 – 4.6) 37.5
partial remission – PR (n=12) 3.51 ± 2.94 2.30 33.3
complete remission – CR (n=53) 2.23 ± 1.45 1.90 20.8
CR after treatment (n=58) 2.35 ± 0.91 2.25 29.3
progression – PROG (n=14) 3.51 ± 3.67 2.60 42.8
control group (n=30) 2.08 ± 0.49 2.05 6.7
** – p < 0.001 vs. control group
* – p < 0.05 vs. control group
# – p < 0.001 vs. CR
Ψ – p < 0.05 vs. after treatment
Figure 1. Changes in serum β2-M levels during antitumour therapy in
children with acute leukaemias and lymphomas
Figure 2. Individual courses of β2-M levels in ten patients treated for
Tu Wilms and SA
Discussion
The clinical applicability of serum β2-M concentration as
a tumour marker in children with cancer has not yet been
assessed. We attempted to find whether β2-M determina-
tion may be of value in the diagnostics and treatment
monitoring in paediatric malignancies. Our data has
shown that the pre-treatment serum concentration of 
β2-M, in the entire group of 100 cancer patients has
significantly exceeded that found in healthy children.
However, when studied separately in each histological
type of neoplasm, the pre-treatment levels of β2-M
behaved differently in lymphoproliferative and solid
neoplasms. In children with ALL, ANLL, HD and NHL
they were significantly higher than in controls, while in Tu
Wilms and SA they remained within normal range.
Similarly, the rates of elevated β2-M values in children
with leukaemias and lymphomas and malignant solid
tumours differed significantly (66.7% and 33.7%, res-
pectively). These results are similar to those reported by
other authors from studies performed on adult cancer
patients. Initial serum concentrations of β2-M have been
reported to be significantly increased in many types of
adult lymphoproliferative disorders, such as: B-cell
chronic lymphoblastic leukaemia, adult T-cell leukaemia,
Hodgkin and non-Hodgkin lymphomas and multiple
myeloma [9-12]. On the contrary, in adults with malignant
solid tumours, the diagnostic usefulness of β2-M is rather
limited [13-15]. It has been suggested, that such varied
behaviour of β2-M concentration in haematological and
solid malignancies may be caused by different biological
sources of this protein. In leukaemias and lymphomas it
may result from the relative overproduction of the β2-M
chains or it may reflect the increased turnover of tumour
cells [16]. It is postulated that in case of solid tumours
increased β2-M levels reflect an enhancement of the
immune system secondary to a malignant process [5, 16].
Perhaps these hypotheses might explain the significant
differences between β2-M concentrations in lympho-
proliferative and solid malignancies of childhood, stated
in our study.
We attempted to find out whether the changes of
β2-M concentrations in the course of antitumour therapy
in paediatric patients correlated with the activity and
clinical phase of cancer. The results observed in the entire
oncological group, show that a good response to treat-
ment is parallel to a significant decrease of the initial 
β2-M concentrations towards the normal range. Literature
reports concerning the significance of β2-M in antitumour
therapy monitoring are scarce and concerned exclusively
with adult patients. Child et al. [10] have shown that
chemotherapy in patients with NHL and HD causes
a reduction in serum β2-M levels even before CR is
achieved. The persistent elevation of β2-M reflects
resistant disease, while its increasing concentrations
reflect relapse. Our results are similar, although the
relatively small number of patients forms a basic
limitation of our study. There have been conflicting
reports concerning β2-M monitoring in solid tumours in
adults. Klein et al. [16] have proven that β2-M concen-
trations correlated with the clinical course of breast
cancer in 365 women. On the contrary, Lotzniker et al.
did not observe any significant differences in β2-M levels
as measured in complete remission and progression
among 186 patients with several types of cancer [15].
The latter data corresponds with the results of our
study, in which, by monitoring β2-M levels we have failed
to differentiate between CR and PROG phases of disease
in childhood malignancies. It may not be ruled out that
the reason for this phenomenon arises from the
heterogeneity of the analysed group of patients, including
both lymphoproliferative and solid neoplasms. It has been
shown here, that the pre-treatment levels of β2-Micro-
globulin and the rates of its elevated values, behave in
a different way in these two histological and clinical
subgroups of neoplasms. The analysis of β2-M changes
during the treatment of children with leukaemias,
lymphomas and solid tumours has also shown that the
individual patterns of β2-M levels differ in those groups of
patients. Preliminary observations indicate that the
significance of β2-Microglobulin in monitoring the
treatment course of paediatric malignant solid tumours is
rather limited, while it may be of particular value among
children with acute leukaemias and lymphomas. However,
to be able to make final conclusions, the monitoring of
serum β2-M in numerous, homogenous group of children
with neoplasm would be necessary.
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